News · 26 weeks50-29%
2026-03-012026-08-23
Mix2590d
- Insider14(56%)
- Other5(20%)
- SEC Filings4(16%)
- Earnings2(8%)
Latest news
25 items- INSIDEREVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 4,025 shares, decreasing direct ownership by 4% to 108,985 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERVP, Chief Accounting Officer Nutt Brian H. covered exercise/tax liability with 937 shares, decreasing direct ownership by 4% to 22,266 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERPresident & COO Njoku Nnamdi covered exercise/tax liability with 3,670 shares and sold $113,609 worth of shares (3,083 units at $36.85) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 161,224 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERCHAIRMAN, CEO Lipps Randall A covered exercise/tax liability with 12,350 shares, decreasing direct ownership by 2% to 511,096 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- SECSEC Form 10-Q filed by Omnicell Inc.10-Q - OMNICELL, INC. (0000926326) (Filer)
- PREnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through VaccinationNew solution may help pharmacies grow monthly vaccinations by up to 66%1 EnlivenHealth, Inc., a subsidiary of Omnicell, Inc. ("EnlivenHealth") and a leading innovator in pharmacy technology and patient engagement solutions, today announced the launch of VaxReach, a proactive vaccine outreach program designed to help pharmacies identify eligible patients and automatically reach them with timely messages that are intended to drive more vaccine traffic into the store. The company will highlight the program at ThoughtSpot 2026, as pharmacies prepare for respiratory and flu season, looking for potentially more efficient ways to turn vaccine opportunities into in-store vaccinations. VaxReach
- SECOmnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMNICELL, INC. (0000926326) (Filer)
- PROmnicell Announces Second Quarter 2026 Financial ResultsOmnicell delivers solid second quarter 2026 financial results Updates full year 2026 guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the second quarter ended June 30, 2026. Second quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, growth in technical services and SaaS-related offerings, and disciplined cost management. Our business performed well during the quarter, with quarterly revenue coming in at the high end of our expectations, and we
- INSIDERCHAIRMAN, CEO Lipps Randall A sold $470,000 worth of shares (10,000 units at $47.00) as part of a pre-agreed trading plan (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- PROmnicell to Release Second Quarter 2026 Financial Results on July 30, 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/ev
- SECSEC Form S-8 filed by Omnicell Inc.S-8 - OMNICELL, INC. (0000926326) (Filer)
- INSIDERPresident & COO Njoku Nnamdi was granted 12,309 shares, increasing direct ownership by 8% to 167,094 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- SECOmnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - OMNICELL, INC. (0000926326) (Filer)
- PRNnamdi Njoku Appointed President of OmnicellNjoku continues to lead global operations and advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnic
- PROmnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services BusinessSeasoned healthcare executive with deep expertise in specialty pharmacy operations named Senior Vice President and General Manager Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Dan Mandoli, a seasoned healthcare executive with more than 30 years of leadership across pharmacy operations and specialty pharmacy services, has joined the Company as Senior Vice President and General Manager, Specialty Pharmacy Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608580918/en/Omnicell Welcomes Dan
- INSIDERDirector Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Scott Bruce E was granted 4,627 shares, increasing direct ownership by 20% to 27,600 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Seim Robin Gene was granted 4,845 shares, increasing direct ownership by 10% to 52,198 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Voynick Eileen J. was granted 4,785 shares, increasing direct ownership by 31% to 20,011 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Parrish Mark W was granted 4,845 shares, increasing direct ownership by 7% to 70,100 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Bauer Joanne B was granted 5,027 shares, increasing direct ownership by 11% to 49,922 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Garrett Mary was granted 5,027 shares, increasing direct ownership by 29% to 22,202 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- INSIDERDirector Ghoshal Kaushik was granted 4,603 shares, increasing direct ownership by 32% to 19,123 units (SEC Form 4)4 - OMNICELL, INC. (0000926326) (Issuer)
- PROmnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying
- SECSEC Form SD filed by Omnicell Inc.SD - OMNICELL, INC. (0000926326) (Filer)
OMCL FAQ
7 questionsWhat does Omnicell Inc. do?
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve...Where does OMCL stock trade?
Omnicell Inc. (OMCL) is listed on NASDAQ.What sector and industry is OMCL in?
Omnicell Inc. operates in the Technology sector, Computer Manufacturing industry.When did Omnicell Inc. go public?
Omnicell Inc. (OMCL) completed its IPO in 2001.What are analysts saying about OMCL?
Omnicell Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-02-04. Recent price targets range from $2800.00 to $3900.00.What companies are similar to OMCL?
Notable peers in the same industry include AAPL (Apple Inc.), DELL (Dell Technologies Inc.), IBM (International Business Machines Corporation), HPQ (HP Inc.), SMCI (Super Micro Computer Inc.). Compare OMCL side-by-side with any of them on Quantisnow.How can I track OMCL on Quantisnow?
Quantisnow aggregates Omnicell Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OMCL to receive live email and push alerts on every new disclosure.